Sandoz Agrees Not To Launch First U.S. Biosimilar Until May

Sandoz has agreed not to launch its filgrastim biosimilar of Amgen's Neupogen until May 11, or a ruling by the Federal Circuit on Amgen's motion for an injunction pending appeal, according to court documents filed at the end of last month. Sandoz's filgrastim last month became the first U.S. biosimilar to receive FDA approval, but marketing of the product has been held up by continued court action. After the U.S. District Court of the Northern District of California ruled against...